Table 1.

CYP2C8 Genotype and Allele Frequencies Among Selected Eritrean Population, 2018

	N	Genotype Frequency (%) (95% CI)						CYP2C8*2 Frequency (%) (95% CI)	CYP2C8*3 Frequency (%) (95% CI)
		*1/*1a	*1/*2	*1/*3	*2/*2	*3/*3	*2/*3
General population	380	82.1 (77.9–85.8)	8.4 (5.8–11.7)	6.3 (4.1–9.3)	1.3 (0.4–3.0)	1.1 (0.3–2.7)	0.8 (0.2–2.3)	5.9 (4.4–7.8)	4.6 (3.2–6.3)
Patients with EPSb	17	76.5 (50.1–93.2)	5.9 (0.1–28.7)	11.8 (1.5–36.4)	–	–	5.9 (0.1–28.7)	5.9 (0.7–19.7)	8.8 (1.9–23.7)

Notes: ^aIn the context of this work, *1 strictly indicates the absence of a *2 or *3 allele. ^bPatients with previous clinically documented artesunate–amodiaquine associated extrapyramidal symptoms.

Abbreviations: N, number of enrolled subjects; CI, confidence interval; CYP, cytochrome P450; EPS, extrapyramidal symptoms.